Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids
Presenter: Dr Sylvia F Boj, Scientific Director, Hubrecht Organoid Technology (HUB)
Organoid technology has enormous potential for oncology research and anticancer agent drug development. Generated from adult stem cells present in normal tissues, organoids recapitulate the physiology of their organ of origin by differentiating in vitro to give rise to functional 3D structures that maintain phenotypic and genotypic characteristics.
Tumor organoids were first described by the Clevers lab, generated from colorectal cancer samples. HUB Organoid protocols are now routinely used and well-published by research groups worldwide.
In this webinar, Dr Sylvia Boj reviews HUB protocols for organoid development. She demonstrates the many advantages of HUB Organoids leading to their predominance of use, and their direct clinical relevance.
Watch this Webinar to Learn:
- The differentiating factors between HUB protocols and other 3D cell culture methods
- The scientific basis behind HUB Organoids providing a relevant platform within organoid technology
- The applications of HUB Organoids including high-throughput screening of anticancer agents and biomarker discovery
- How HUB Organoid in vitro response directly correlates with the clinical outcome of the original patient
- About a novel organoid and immune cell co-culture system for studying the effects of immune modulating drugs
Who Should Watch:
- Scientists interested in using in vitro models that recapitulate a human organ’s function in vivo
- Scientists developing anticancer agents who want to learn more about the development and translatability of organoids
- Drug developers who want to learn how organoids can be expanded in large scale for high throughput screening
About The Presenter:
Sylvia F Boj, Scientific Director, Hubrecht Organoid Technology (HUB) received her PhD in 2006 at the University of Barcelona, Spain for her work at IDIBAPS on functional genetic analysis for deciphering the transcriptional role of MODY genes in pancreatic beta cells.
With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 regulating metabolism. Following this, she established an in vitro organoid model for human pancreatic cancers.
In 2014, she moved to Hubrecht Organoid Technology (Utrecht, the Netherlands) as a Group Leader for Cystic Fibrosis and Cancer programs. In 2016, she was appointed as Scientific Director of the HUB, with the ultimate goal of transferring scientific advances in organoid technology to the development of new drugs, by interacting with pharmaceutical companies, and developing clinical trials to validate the predictive value of the organoids for patients response to certain treatments.